TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma

Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer

(2019) Young Shin Song et al.   ENDOCRINE-RELATED CANCER

Pediatric low-grade gliomas can be molecularly stratified for risk

(2018) Rui Ryan Yang et al.   ACTA NEUROPATHOLOGICA

Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial

(2018) Alan Mackay et al.   CANCER CELL

TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma

(2018) Sabine Spiegl-Kreinecker et al.   NEURO-ONCOLOGY

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer

(2018) Rengyun Liu et al.   Nature Communications

The genetic landscape of anaplastic pleomorphic xanthoastrocytoma

(2018) Joanna J. Phillips et al.   BRAIN PATHOLOGY

Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner

(2018) Andrew Mancini et al.   CANCER CELL

TERT promoter mutation subtypes and survival in stage I and II melanoma patients

(2018) Juan J. Andrés-Lencina et al.   INTERNATIONAL JOURNAL OF CANCER

Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1

(2018) Xueyong Xu et al.   Nature Communications

BRAF V600E, TERT, and IDH2 mutations in pleomorphic xanthoastrocytoma: Observations from a large case-series study

(2018) Chengxin Ma et al.   World Neurosurgery

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

(2018) Thomas Kaley et al.   JOURNAL OF CLINICAL ONCOLOGY

COSMIC: the Catalogue Of Somatic Mutations In Cancer

(2018) John G Tate et al.   NUCLEIC ACIDS RESEARCH

Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas

(2017) Alvaro Lassaletta et al.   JOURNAL OF CLINICAL ONCOLOGY

TERT promoter mutations in telomere biology

(2017) Barbara Heidenreich et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain

(2017) Johannes Gojo et al.   NEURO-ONCOLOGY

Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis

(2017) Shinje Moon et al.   THYROID

Xenotransplantation of pediatric low grade gliomas confirms the enrichment of BRAF V600E mutation and preservation of CDKN2A deletion in a novel orthotopic xenograft mouse model of progressive pleomorphic xanthoastrocytoma

(2017) Mari Kogiso et al.   Oncotarget

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma

(2016) Nozomi Matsumura et al.   NEUROPATHOLOGY

Derepression ofhTERTgene expression promotes escape from oncogene-induced cellular senescence

(2016) Priyanka L. Patel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activation of mutantTERTpromoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas

(2016) Yinghui Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing

(2016) Florian Selt et al.   Oncotarget

TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation

(2016) Andrelou F. Vallarelli et al.   Oncotarget

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model

(2016) Stefan Grossauer et al.   Oncotarget

Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells

(2015) Nagarathinam Selvaraj et al.   Cell Communication and Signaling

BRAFMutation andCDKN2ADeletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma

(2015) Matthew Mistry et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma

(2015) Tina Dasgupta et al.   JOURNAL OF NEURO-ONCOLOGY

Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis

(2015) Sabine Spiegl-Kreinecker et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

(2015) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer

(2015) R. J. A. Bell et al.   SCIENCE

Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation

(2015) Veronique Mathieu et al.   Oncotarget

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

(2014) Giles W Robinson et al.   BMC CANCER

BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence

(2014) Mingzhao Xing et al.   JOURNAL OF CLINICAL ONCOLOGY

ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells

(2014) Joshua P. Plotnik et al.   NUCLEIC ACIDS RESEARCH

Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors

(2014) J. M. M. Levy et al.   Cancer Discovery

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system

(2013) Christian Koelsche et al.   ACTA NEUROPATHOLOGICA

Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series

(2013) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

Tumor adaptation and resistance to RAF inhibitors

(2013) Piro Lito et al.   NATURE MEDICINE

BRAF-V600E mutation in pediatric and adult glioblastoma

(2013) S. Dahiya et al.   NEURO-ONCOLOGY

Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age

(2013) Daniela Lötsch et al.   NEURO-ONCOLOGY

Vemurafenib in pediatric patients withBRAFV600Emutated high-grade gliomas

(2013) Francisco Bautista et al.   PEDIATRIC BLOOD & CANCER

Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy

(2012) E. Huillard et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

(2011) Genevieve Schindler et al.   ACTA NEUROPATHOLOGICA

Targeted Therapy for BRAFV600E Malignant Astrocytoma

(2011) T. P. Nicolaides et al.   CLINICAL CANCER RESEARCH

Phosphorylation of the Transcription Factor Ets-1 by ERK2: Rapid Dissociation of ADP and Phospho-Ets-1

(2010) Kari Callaway et al.   BIOCHEMISTRY

A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma

(2009) Hayriye V Erkizan et al.   NATURE MEDICINE

Tandem Duplication Producing a Novel OncogenicBRAFFusion Gene Defines the Majority of Pilocytic Astrocytomas

(2008) David T.W. Jones et al.   CANCER RESEARCH